Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study

Although immune-checkpoint inhibitors (ICIs) have become an important choice of treatment for advanced NSCLC, recent reports show hyperprogressive disease (HPD) after ICI administration. The clinico-pathological features of HPD still remain unclear. Here we report a 65-year-old man with lung adenoca...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yuko, Matsubara, Osamu, Asada, Kazuhiro, Muramatsu, Aya, Suzuki, Makoto, Shirai, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586950/
https://www.ncbi.nlm.nih.gov/pubmed/31249779
http://dx.doi.org/10.1016/j.rmcr.2019.100885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586950/
https://www.ncbi.nlm.nih.gov/pubmed/31249779
http://dx.doi.org/10.1016/j.rmcr.2019.100885

Ejemplares similares